Finance entity

House Select Committee on China

organization

Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.4 in the same window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · House Select Committee on China

1 story
8 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about House Select Committee on China

Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.4 in the same window. Source depth averages 3 original sources per story, versus 2.7 across the same-window beat baseline. We currently track 1 Finance story that mention House Select Committee on China, all published on March 19, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering House Select Committee on China. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning House Select Committee on China 1

Financial Regulation Bearish

US Lawmakers Sound Alarm Over Chinese Dominance in Pharmaceutical Supply Chain

The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.

3 sources

House Select Committee on China is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.